Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 290: 147-58, 2015 Apr 02.
Article in English | MEDLINE | ID: mdl-25637808

ABSTRACT

Understanding the molecular mechanisms that promote stress resilience might open up new therapeutic avenues to prevent stress-related disorders. We recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A). DRR1 is expressed in the mouse brain; it is up-regulated by stress and glucocorticoids and modulates neuronal actin dynamics. In the adult mouse, DRR1 was shown to facilitate specific behaviors which might be protective against some of the deleterious consequences of stress exposure: in the hippocampal CA3 region, DRR1 improved cognitive performance whereas in the septum, it specifically increased social behavior. Therefore DRR1 was suggested as a candidate protein promoting stress-resilience. Fam107B (family with sequence similarity 107, member B) is the unique paralog of DRR1, and both share high sequence similarities, predicted glucocorticoid response elements, heat-shock induction and tumor suppressor properties. So far, the role of Fam107B in the central nervous system was not studied. The aim of the present investigation, therefore, was to analyze whether Fam107B and DRR1 display comparable mRNA expression patterns in the brain and whether both are modulated by stress and glucocorticoids. Spatio-temporal mapping of Fam107B mRNA expression in the embryonic and adult mouse brain, by means of in situ hybridization, showed that Fam107B was expressed during embryogenesis and in the adulthood, with particularly high and specific expression in the forming telencephalon suggestive of an involvement in corticogenesis. In the adult mouse, expression was restricted to neurogenic niches, like the dentate gyrus. In contrast to DRR1, Fam107B mRNA expression failed to be modulated by glucocorticoids and social stress in the adult mouse. In summary, Fam107B and DRR1 show different spatio-temporal expression patterns in the central nervous system, suggesting at least partially different functional roles in the brain, and where the glucocorticoid receptor (GR)-induced regulation appears to be a unique property of DRR1.


Subject(s)
Brain/growth & development , Brain/metabolism , Stress, Psychological/metabolism , Tumor Suppressor Proteins/metabolism , Acute Disease , Amino Acid Sequence , Animals , Brain/drug effects , Chronic Disease , Dexamethasone/pharmacology , Dominance-Subordination , Glucocorticoids/pharmacology , In Situ Hybridization , Male , Mice , Mice, Inbred C57BL , Molecular Sequence Data , RNA, Messenger/metabolism , Receptors, Glucocorticoid/agonists , Receptors, Glucocorticoid/metabolism , Sequence Homology, Amino Acid , Stem Cell Niche/drug effects , Stem Cell Niche/physiology , Time Factors , Tumor Suppressor Proteins/genetics
2.
Neuroscience ; 163(4): 1012-23, 2009 Nov 10.
Article in English | MEDLINE | ID: mdl-19635527

ABSTRACT

The embryonic mid-hindbrain organizer, which is composed of a transient cell population in the brainstem, controls the development of dopaminergic and serotonergic neurons. Different genes determining the position and activity of this embryonic structure have been implicated in dopamine- and serotonin-associated disorders. Mouse mutants with a caudally shifted mid-hindbrain organizer, are hyperactive, show increased numbers of dopaminergic neurons and a reduction in serotonergic cells. In the present study we used these mutants to gain insights into the genetic and developmental mechanisms underlying motor activity and the response to psychostimulants. To this end, we studied the motor activity of these animals after exposure to methylphenidate and amphetamine and characterized their dopaminergic and serotonergic innervation. Saline-treated mutants showed increased locomotion, more stereotypic behavior and a decrease in rearing compared to wild-type mice. This baseline level of activity was similar to behaviors observed in wild-type animals treated with high doses of psychostimulants. In mutants methylphenidate (5 or 30 mg/kg) or amphetamine (2 or 4 mg/kg) did not further increase activity or even caused a decrease of locomotor activity, in contrast to wild-type mice. Fluoxetine (5 or 10 mg/kg) reduced hyperactivity of mutants to levels observed in wild-types. Transmitter measurements, dopamine and serotonin transporter binding assays and autoradiography, indicated a subtle increase in striatal dopaminergic innervation and a marked general decrease of serotonergic innervation in mutants. Taken together, our data suggest that mice with an aberrantly positioned mid-hindbrain organizer show altered sensitivity to psychostimulants and that an increase of serotonergic neurotransmission reverses their hyperactivity. We conclude that the mid-hindbrain organizer, by orchestrating the formation of dopaminergic and serotonergic neurons, is an essential developmental parameter of locomotor activity and psychostimulant response.


Subject(s)
Amphetamine/pharmacology , Central Nervous System Stimulants/pharmacology , Methylphenidate/pharmacology , Motor Activity/drug effects , Rhombencephalon/drug effects , Amphetamine/administration & dosage , Animals , Brain/drug effects , Brain/physiology , Central Nervous System Stimulants/administration & dosage , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins/metabolism , Dose-Response Relationship, Drug , Male , Methylphenidate/administration & dosage , Mice , Mice, Inbred Strains , Mice, Mutant Strains , Motor Activity/physiology , Neurons/drug effects , Neurons/physiology , Rhombencephalon/physiology , Serotonin/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism
3.
Proc Natl Acad Sci U S A ; 97(17): 9683-8, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10931939

ABSTRACT

Neurotrophins influence the epigenetic shaping of the vertebrate nervous system by regulating neuronal numbers during development and synaptic plasticity. Here we attempt to determine whether these growth factors can also regulate neurotransmitter plasticity. As a model system we used the selection between noradrenergic and cholinergic neurotransmission by paravertebral sympathetic neurons. Developing sympathetic neurons express the neurotrophin receptors TrkA and TrkC, two highly related receptor tyrosine kinases. Whereas the TrkA ligand nerve growth factor (NGF) has long been known to regulate both the survival and the expression of noradrenergic traits in sympathetic neurons, the role of TrkC and of its ligand neurotrophin-3 (NT3) has remained unclear. We found that TrkC expression in the avian sympathetic chain overlaps substantially with that of choline acetyltransferase. In sympathetic chain explants, transcripts of the cholinergic marker genes choline acetyltransferase and vasoactive intestinal polypeptide were strongly enriched in the presence of NT3 compared with NGF, whereas the noradrenergic markers tyrosine hydroxylase and norepinephrine transporter were reduced. The transcription factor chicken achaete scute homolog 1 was coexpressed with cholinergic markers. The effects of NT3 are reversed and antagonized by NGF. They are independent of neuronal survival and developmentally regulated. These results suggest a role for NT3 as a differentiation factor for cholinergic neurons and establish a link between neurotrophins and neurotransmitter plasticity.


Subject(s)
Avian Proteins , Cell Differentiation/drug effects , Ganglia, Sympathetic/cytology , Neurons/drug effects , Neurotrophin 3/pharmacology , Receptor, trkC/metabolism , Symporters , Animals , Basic Helix-Loop-Helix Transcription Factors , Blotting, Western , Carrier Proteins/genetics , Cell Death/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Chick Embryo , Choline O-Acetyltransferase/genetics , Choline O-Acetyltransferase/metabolism , Ciliary Neurotrophic Factor/pharmacology , Culture Techniques , DNA-Binding Proteins/genetics , Ganglia, Sympathetic/drug effects , Ganglia, Sympathetic/metabolism , Gene Expression Regulation/drug effects , Homeodomain Proteins/genetics , Immunohistochemistry , In Situ Hybridization , Nerve Growth Factor/pharmacology , Nerve Tissue Proteins , Neurites/drug effects , Neurites/metabolism , Neurons/cytology , Neurons/metabolism , Neurotrophin 3/antagonists & inhibitors , Neurotrophin 3/metabolism , Norepinephrine Plasma Membrane Transport Proteins , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor, trkA/genetics , Receptor, trkC/genetics , Transcription Factors/genetics , Tyrosine 3-Monooxygenase/genetics , Vasoactive Intestinal Peptide/genetics
4.
Schizophr Res ; 20(1-2): 175-80, 1996 May.
Article in English | MEDLINE | ID: mdl-8794507

ABSTRACT

This study explores the genetic relationship between schizophrenia and the dopamine transporter gene (DAT) by a variety of methods. In a sample of 48 families--each family containing at least one nuclear family with a pair of affected siblings--we performed linkage analysis using the maximum likelihood (LOD score) method as well as sibpair analysis (identity by descent). In addition, we investigated a sample of 108 nuclear families--index case affected with schizophrenia/chronic schizoaffective disorder--for association using the haplotype relative risk method. Linkage between schizophrenia and DAT using two- and three-point linkage analysis was excluded with all disease models employed. No evidence for association between haplotypes of the VNTR-probe of the DAT and schizophrenia has been detected. Thus, a contribution of the DAT gene to the genetic diathesis of schizophrenia is unlikely in the families studied.


Subject(s)
Carrier Proteins/genetics , Genetic Linkage/genetics , Membrane Glycoproteins , Membrane Transport Proteins , Nerve Tissue Proteins , Schizophrenia/genetics , Adult , Chronic Disease , Dopamine Plasma Membrane Transport Proteins , Female , Genetic Markers/genetics , Genotype , Humans , Likelihood Functions , Male , Minisatellite Repeats/genetics , Models, Genetic , Phenotype , Psychotic Disorders/diagnosis , Psychotic Disorders/genetics , Risk Factors , Schizophrenia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...